Skip to content

RARE · Ultragenyx Pharmaceutical Inc.

Healthcare · −4.2% on Oct 16

☆ Add to watchlist

Updated Oct 17 · 9 feeds behind: FDA drug approvals, 1 day, and 8 more · Every feed →

On this page

The market view

Price chart

The interactive RARE chart (by TradingView) loads here.

Our take

None of our tested rules has picked RARE yet.

The 0–100 score for RARE
Members see one number for how strongly these rules agree on RARE, and the day each rule fired. Better-tested rules count more, and so do different kinds of filings that point the same way.
See pricing →
Already a member? Sign in

Compare with this company’s history

Is disclosure activity unusual?

See how many different insiders or members of Congress reported purchases or sales of RARE. Each bar covers 28 days, by disclosure date. Several trades by one person count once in each group and period.

Latest period: Sep 21, 2026–Oct 18, 2026 · UTC dates · today is excluded

Congress purchases

Sparse history

Only 2 of 12 earlier periods had activity. That is too little recurring activity to label this count unusual.

Latest 28 days
1
Earlier median
0
Earlier range
0–1
Distinct filers per 28 daysScale: 0–1
Oct 20, 2025Oct 18, 2026
Earlier periodsLatest 28 daysEarlier median 0

Who appears in the latest period?

Up to three filers; one example disclosure each.

Inspect this period’s filings

The history behind this view

First stored company disclosure: Aug 13, 2025. Newest disclosure across this feed: Oct 15, 2026.

Earlier periods in the comparison: 12. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.

Exact counts, dates and filings for all four categories
Insider purchases · Short history

Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 0; range: 0–0.

Insider purchases: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 20, 2025–Nov 16, 2025—Unavailable
Nov 17, 2025–Dec 14, 2025—Unavailable
Dec 15, 2025–Jan 11, 2026—Unavailable
Jan 12, 2026–Feb 8, 2026—Unavailable
Feb 9, 2026–Mar 8, 2026—Unavailable
Mar 9, 2026–Apr 5, 2026—Unavailable
Apr 6, 2026–May 3, 2026—Unavailable
May 4, 2026–May 31, 2026—Unavailable
Jun 1, 2026–Jun 28, 20260Partial; excluded
Jun 29, 2026–Jul 26, 20260Within stored history
Jul 27, 2026–Aug 23, 20260Within stored history
Aug 24, 2026–Sep 20, 20260Within stored history
Sep 21, 2026–Oct 18, 2026Latest period0Within stored history
Insider sales · Short history

Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 1; range: 1–2.

Insider sales: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 20, 2025–Nov 16, 2025—Unavailable
Nov 17, 2025–Dec 14, 2025—Unavailable
Dec 15, 2025–Jan 11, 2026—Unavailable
Jan 12, 2026–Feb 8, 2026—Unavailable
Feb 9, 2026–Mar 8, 2026—Unavailable
Mar 9, 2026–Apr 5, 2026—Unavailable
Apr 6, 2026–May 3, 2026—Unavailable
May 4, 2026–May 31, 2026—Unavailable
Jun 1, 2026–Jun 28, 20262Partial; excluded
Jun 29, 2026–Jul 26, 20261Within stored history
Jul 27, 2026–Aug 23, 20262Within stored history
Aug 24, 2026–Sep 20, 20261Within stored history
Sep 21, 2026–Oct 18, 2026Latest period0Within stored history
Congress purchases · Sparse history

Only 2 of 12 earlier periods had activity. That is too little recurring activity to label this count unusual. Earlier median: 0; range: 0–1.

Congress purchases: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 20, 2025–Nov 16, 20250Within stored history
Nov 17, 2025–Dec 14, 20250Within stored history
Dec 15, 2025–Jan 11, 20260Within stored history
Jan 12, 2026–Feb 8, 20260Within stored history
Feb 9, 2026–Mar 8, 20261Within stored history
Mar 9, 2026–Apr 5, 20260Within stored history
Apr 6, 2026–May 3, 20261Within stored history
May 4, 2026–May 31, 20260Within stored history
Jun 1, 2026–Jun 28, 20260Within stored history
Jun 29, 2026–Jul 26, 20260Within stored history
Jul 27, 2026–Aug 23, 20260Within stored history
Aug 24, 2026–Sep 20, 20260Within stored history
Sep 21, 2026–Oct 18, 2026Latest period1Within stored history
Congress sales · Sparse history

Only 0 of 12 earlier periods had activity. That is too little recurring activity to label this count unusual. Earlier median: 0; range: 0–0.

Congress sales: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 20, 2025–Nov 16, 20250Within stored history
Nov 17, 2025–Dec 14, 20250Within stored history
Dec 15, 2025–Jan 11, 20260Within stored history
Jan 12, 2026–Feb 8, 20260Within stored history
Feb 9, 2026–Mar 8, 20260Within stored history
Mar 9, 2026–Apr 5, 20260Within stored history
Apr 6, 2026–May 3, 20260Within stored history
May 4, 2026–May 31, 20260Within stored history
Jun 1, 2026–Jun 28, 20260Within stored history
Jun 29, 2026–Jul 26, 20260Within stored history
Jul 27, 2026–Aug 23, 20260Within stored history
Aug 24, 2026–Sep 20, 20260Within stored history
Sep 21, 2026–Oct 18, 2026Latest period0Within stored history
How to read this comparison

The median is the middle count in up to 12 earlier, non-overlapping 28-day periods; the range runs from the smallest to the largest count. The latest period is excluded from both. A comparison needs at least 6 earlier periods, including 3 with activity. The feed’s latest disclosure must be within 7 days of the current period’s end. This freshness check does not verify complete collection.

Insiders include individuals and reporting entities; only purchase and sale codes enter this view. Congress counts reporting members, including their disclosed family transactions. The same filer can appear in purchases and sales, so these categories should not be added into a net count.

These are stored disclosures, not a complete measure of trading. Reporting delays and collection gaps can change the comparison. More activity does not identify a motive or predict a stock’s return.

Company timeline

What has been happening?

May 1, 2026–Oct 16, 2026. Select a month in a category to inspect its records.

Company filings

Insiders

Public officials

Owners & lobbying

Company filings · Oct 2026

  1. Filed
  2. Filed
All 23 records in this snapshot
  1. Filed
  2. Disclosed
    Gilbert Ray Cisneros Jr · Purchase

    Transaction dated Sep 29, 2026

  3. Filed
  4. Filed
  5. Filed
  6. Disclosed
    Theodore Alan Huizenga · Sale

    Transaction dated Sep 15, 2026

  7. Disclosed
    Theodore Alan Huizenga · Sale

    Transaction dated Sep 3, 2026

  8. Filed
  9. Filed
  10. Filed
  11. Filed
  12. Filed
  13. Disclosed
    Howard Horn · Sale

    Transaction dated Aug 3, 2026

  14. Disclosed
    Karah Herdman Parschauer · Sale

    Transaction dated Aug 3, 2026

  15. Filed
  16. Filed
  17. Disclosed
    Howard Horn · Sale

    Transaction dated Jul 1, 2026

  18. Filed
  19. Disclosed
    Corazon (Corsee) D. Sanders · Sale

    Transaction dated Jun 15, 2026

  20. Disclosed
    Karah Herdman Parschauer · Sale

    Transaction dated Jun 15, 2026

  21. Filed
  22. Filed
  23. Filed

Month counts include every record on file. The lists show the newest records on this page. A dash means none on file that month. Trades use disclosure dates; contract dates follow the source record. Nearby events do not establish the cause of a price move.

Who's buying and selling · last 90 days

Congress

1 member bought, none sold · 1 Dem

  1. ▲ BUYGilbert Ray Cisneros Jr Dem · House · CARARE Ultragenyx Pharmaceutical Inc.$1K–$15Kdisclosed Oct 9 · filed 10 days after the trade
See every Congress trade on RARE →

Company insiders

0 buys · 4 sells · $184K sold

  1. ▼ SELLTheodore Alan Huizenga SVP, Chief Accounting OfficerRARE Ultragenyx Pharmaceutical Inc.$17.4Kdisclosed Sep 15 · filed the same day
  2. ▼ SELLTheodore Alan Huizenga SVP, Chief Accounting OfficerRARE Ultragenyx Pharmaceutical Inc.$2.3Kdisclosed Sep 8 · filed 5 days after the trade · late
  3. ▼ SELLHoward Horn Chief Financial OfficerRARE Ultragenyx Pharmaceutical Inc.$117Kdisclosed Aug 4 · filed 1 day after the trade
  4. ▼ SELLKarah Herdman Parschauer EVP and Chief Legal OfficerRARE Ultragenyx Pharmaceutical Inc.$47.3Kdisclosed Aug 4 · filed 1 day after the trade
See every insider trade on RARE →

Big holders (Schedule 13D / 13G): 4 filings in the last 90 days · newest: Rtw Investments, LP (13G), Aug 14, 2026 ↗

Filings & events

Company filings (8-K) 82

Events the company must report to the SEC within days — results, deals, departures, restatements.

What it files 8-Ks about

  • Other events · item 8.0128
  • Quarterly or yearly results · item 2.0212
  • Signed a major agreement · item 1.015
  • Directors or officers joined, left or got new pay · item 5.025
  • Shared information with investors · item 7.014
  • Shareholder vote results · item 5.073

Filing red flags 22

Warning signs in the company's own SEC filings — going-concern doubts, control weaknesses, staff comment letters, late filings, restatements, Wells notices, clinical holds, dividend cuts.

Lobbying 21

Lobbying reports filed with the Senate for the company.

$1.8M across 21 reports

Issues named in the most reports

  • Health Issues 18
  • Budget/Appropriations 7
  • Medicare/Medicaid 5
  • Medical/Disease Research/Clinical Labs 2

Planned insider sales (Form 144) 30

Notices insiders file before they sell certain shares, such as ones they got straight from the company.

2 in the last 90 days · 30 notices on file

The notices on file don't give the sale's size; each sale shows up under company insiders once it is reported.

5% owners (13D / 13G) 7

Investors who reported owning 5% or more — 13D for owners who may push for changes, 13G for owners who just hold.

Push for changes, or just hold?

  • 13D, may push for changes: 0 filings
  • 13G, just holds: 7 filings

Filed most: State Street Corp (2) · Rtw Investments, LP (1) · Aqr Capital Management LLC (1) · Vanguard Capital Management LLC (1)

Biggest named funds (13F)

The largest RARE holdings among the well-known funds whose quarterly 13F filings we read — opens here.

Every disclosed trade on RARE

  1. ▲ BUYGilbert Ray Cisneros Jr Dem · House · CARARE Ultragenyx Pharmaceutical Inc.$1K–$15Kdisclosed Oct 9 · filed 10 days after the trade
  2. ▼ SELLTheodore Alan Huizenga SVP, Chief Accounting OfficerRARE Ultragenyx Pharmaceutical Inc.$17.4Kdisclosed Sep 15 · filed the same day
  3. ▼ SELLTheodore Alan Huizenga SVP, Chief Accounting OfficerRARE Ultragenyx Pharmaceutical Inc.$2.3Kdisclosed Sep 8 · filed 5 days after the trade · late
  4. ▼ SELLHoward Horn Chief Financial OfficerRARE Ultragenyx Pharmaceutical Inc.$117Kdisclosed Aug 4 · filed 1 day after the trade
  5. ▼ SELLKarah Herdman Parschauer EVP and Chief Legal OfficerRARE Ultragenyx Pharmaceutical Inc.$47.3Kdisclosed Aug 4 · filed 1 day after the trade
  6. ▼ SELLHoward Horn Chief Financial OfficerRARE Ultragenyx Pharmaceutical Inc.$156Kdisclosed Jul 6 · filed 5 days after the trade · late
  7. ▼ SELLCorazon (Corsee) D. Sanders DirectorRARE Ultragenyx Pharmaceutical Inc.$50.1Kdisclosed Jun 15 · filed the same day
  8. ▼ SELLKarah Herdman Parschauer EVP and Chief Legal OfficerRARE Ultragenyx Pharmaceutical Inc.$46.8Kdisclosed Jun 15 · filed the same day
  9. ▲ BUYGilbert Ray Cisneros Jr Dem · House · CARARE Ultragenyx Pharmaceutical Inc.$1K–$15Kdisclosed Apr 6 · filed 34 days after the trade
  10. ▲ BUYGilbert Ray Cisneros Jr Dem · House · CARARE Ultragenyx Pharmaceutical Inc.$1K–$15Kdisclosed Mar 6 · filed 16 days after the trade
  11. ▲ BUYGilbert Ray Cisneros Jr Dem · House · CARARE Ultragenyx Pharmaceutical Inc.$1K–$15Kdisclosed Sep 8, 2025 · filed 31 days after the trade
  12. ▲ BUYGilbert Ray Cisneros Jr Dem · House · CARARE Ultragenyx Pharmaceutical Inc.$1K–$15Kdisclosed Aug 13, 2025 · filed 29 days after the trade
See the trades on RARE in the feed →
People & votes

Which members of Congress traded RARE, sponsored bills that touch it and voted on them — opens here.